TORONTO, June 27, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF), today announced that all of the nominees listed in the Management Information Circular of Concordia, dated May 23, 2014, for the 2014 Annual and Special Meeting of Shareholders held on June 27, 2014, in Toronto, Ontario, (the "Meeting") were elected as Directors of Concordia. The six (6) candidates nominated for election were elected by a majority of the shareholders present in person or represented by proxy at the Meeting, as follows:
|Votes For||Votes Withheld|
|Mark L. Thompson||17,429,010||99.986%||2,525||0.014%|
In addition, at the Meeting all resolutions put to vote were passed, including the resolutions relating to the amendment to Concordia's Stock Option Plan and the adoption of Concordia's Long Term Incentive Plan.
Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. Concordia's legacy pharmaceutical business consists of Donnatal®, an adjunctive therapy in the treatment of IBS and acute enterocolitis, an ADHD-treatment drug, Kapvay® (clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin® in the United States.
Concordia operates out of facilities in Oakville, Ontario, Bridgetown, Barbados, Lenexa, Kansas (near Kansas City, Missouri), Bannockburn (near Chicago), Illinois, and Charlottesville, Virginia.
SOURCE Concordia Healthcare Corp.